Research
Cost-effectiveness of the use of low- and high-potency statins in people at low cardiovascular risk
Jon Conly, Fiona Clement, Marcello Tonelli, Brenda Hemmelgarn, Scott Klarenbach, Anita Lloyd, Finlay A. McAlister, Don Husereau, Natasha Wiebe, Flora Au and Braden Manns
CMAJ November 08, 2011 183 (16) E1180-E1188; DOI: https://doi.org/10.1503/cmaj.101281
Jon Conly
BA
Fiona Clement
PhD
Marcello Tonelli
MD SM
Brenda Hemmelgarn
MD PhD
Scott Klarenbach
MD MSc
Anita Lloyd
MSc
Finlay A. McAlister
MD MSc
Don Husereau
BScPharm MSc
Natasha Wiebe
MMath PStat
Flora Au
Mec
Braden Manns
MD MSc
![Loading Loading](https://www.cmaj.ca/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif)
Submit a Response to This Article
Jump to comment:
No Responses have been published for this article.
In this issue
Article tools
Cost-effectiveness of the use of low- and high-potency statins in people at low cardiovascular risk
Jon Conly, Fiona Clement, Marcello Tonelli, Brenda Hemmelgarn, Scott Klarenbach, Anita Lloyd, Finlay A. McAlister, Don Husereau, Natasha Wiebe, Flora Au, Braden Manns
CMAJ Nov 2011, 183 (16) E1180-E1188; DOI: 10.1503/cmaj.101281
Cost-effectiveness of the use of low- and high-potency statins in people at low cardiovascular risk
Jon Conly, Fiona Clement, Marcello Tonelli, Brenda Hemmelgarn, Scott Klarenbach, Anita Lloyd, Finlay A. McAlister, Don Husereau, Natasha Wiebe, Flora Au, Braden Manns
CMAJ Nov 2011, 183 (16) E1180-E1188; DOI: 10.1503/cmaj.101281
Jump to section
Related Articles
Cited By...
- When Is Carotid Angioplasty and Stenting the Cost-Effective Alternative for Revascularization of Symptomatic Carotid Stenosis? A Canadian Health System Perspective
- Statins and the Risk of Hepatocellular Carcinoma in Patients With Hepatitis C Virus Infection
- The efficacy and cost-effectiveness of statins in low-risk patients